bpc-157 multiple sclerosis clinical trial trials for progressive sclerosis: progress, new lessons learned, and remaining challenges Sample of patents with BPC

Peptides were then scored based on binding energies, with four identified (S37, S61, S62, S71) that were found to inhibit amyloid formation in vitro [78]

Below are options that show up a lot in clinics and labs

and its mechanism of action is felt to be similar to that of 5-alpha reductase inhibitors

However, direct agonist stimulation of dopaminergic receptors present on NSCs in the SVZ, to promote adult neurogenesis, may represent the most clinically promising approach for PD patients when taking into consideration the substantial loss of dopaminergic neurons at the time of disease diagnosis [113, 127]

L.et al (2004b)